• On July 16, 2021, the Paris Court had assigned Biophytis a penalty payment of 1,500,000 euros in favor of Negma Group Ltd, following a judgment by the Paris Commercial Court
• On September 8, 2022, the Paris Court of Appeal partially overturns the judgment of the Execution Judge of the Paris Court
• Negma Group Ltd is ordered to return to Biophytis the sum of 1 million euros
Paris (France), Cambridge (Massachusetts, US), September 13, 2022, 8:00 a.m. – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a specialized clinical-stage biotechnology company in the development of treatments aimed at slowing the degenerative processes associated with aging, including respiratory failure in patients suffering from COVID-19, announces that the Paris Court of Appeal has rendered a judgment on September 8, 2022 in the case between Biophytis and Negma Group Ltd.